- Home
- ME vs CRVO Comparison
ME vs CRVO Comparison
Compare ME & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ME
- CRVO
- Stock Information
- Founded
- ME 2006
- CRVO 2001
- Country
- ME United States
- CRVO United States
- Employees
- ME N/A
- CRVO N/A
- Industry
- ME Precision Instruments
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ME Health Care
- CRVO Health Care
- Exchange
- ME Nasdaq
- CRVO Nasdaq
- Market Cap
- ME 98.7M
- CRVO 98.3M
- IPO Year
- ME N/A
- CRVO N/A
- Fundamental
- Price
- ME $3.39
- CRVO $2.13
- Analyst Decision
- ME Hold
- CRVO Buy
- Analyst Count
- ME 1
- CRVO 8
- Target Price
- ME $9.40
- CRVO $38.75
- AVG Volume (30 Days)
- ME 219.4K
- CRVO 476.7K
- Earning Date
- ME 02-05-2025
- CRVO 11-12-2024
- Dividend Yield
- ME N/A
- CRVO N/A
- EPS Growth
- ME N/A
- CRVO N/A
- EPS
- ME N/A
- CRVO N/A
- Revenue
- ME $193,260,000.00
- CRVO $10,066,550.00
- Revenue This Year
- ME $21.93
- CRVO $34.17
- Revenue Next Year
- ME $17.31
- CRVO N/A
- P/E Ratio
- ME N/A
- CRVO N/A
- Revenue Growth
- ME N/A
- CRVO 116.29
- 52 Week Low
- ME $2.66
- CRVO $1.80
- 52 Week High
- ME $16.52
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- ME 44.56
- CRVO 28.45
- Support Level
- ME $3.15
- CRVO $1.99
- Resistance Level
- ME $4.18
- CRVO $2.43
- Average True Range (ATR)
- ME 0.26
- CRVO 0.17
- MACD
- ME 0.05
- CRVO 0.31
- Stochastic Oscillator
- ME 29.46
- CRVO 26.92
About ME 23andMe Holding Co.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.